Abstract
The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 654-663 |
| Number of pages | 10 |
| Journal | Clinical Transplantation |
| Volume | 29 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2015 |
Fingerprint
Keywords
- Everolimus
- Immunosuppression
- Malignancy
- Mammalian target of rapamycin inhibitor
- Sirolimus
- Transplant
ASJC Scopus subject areas
- Transplantation
Cite this
Mammalian target of rapamycin inhibition after solid organ transplantation : Can it, and does it, reduce cancer risk? / Bhat, Mamatha; Watt, Kymberly D.
In: Clinical Transplantation, Vol. 29, No. 7, 01.07.2015, p. 654-663.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Mammalian target of rapamycin inhibition after solid organ transplantation
T2 - Can it, and does it, reduce cancer risk?
AU - Bhat, Mamatha
AU - Watt, Kymberly D.
PY - 2015/7/1
Y1 - 2015/7/1
N2 - The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.
AB - The mammalian target of rapamycin (mTOR) inhibitors sirolimus and everolimus has been increasingly used as immunosuppressants for recipients of solid organ transplants. Over the years, potential advantages unique to this class of immunosuppressants have been recognized, including chemoprevention by virtue of their antiproliferative effects. Prevention of malignancy after transplant through mTOR inhibitor-based immunosuppression may have a specific practical application in transplant recipients with preexisting malignancy including hepatocellular carcinoma or cholangiocarcinoma. This review will reveal how the biochemistry of the mTOR pathway, as it pertains to chemoprevention, can support a clinical role for mTOR inhibitors in the prevention of malignancies, recurrent or de novo, after solid organ transplantation in selected patients.
KW - Everolimus
KW - Immunosuppression
KW - Malignancy
KW - Mammalian target of rapamycin inhibitor
KW - Sirolimus
KW - Transplant
UR - http://www.scopus.com/inward/record.url?scp=84937162112&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84937162112&partnerID=8YFLogxK
U2 - 10.1111/ctr.12559
DO - 10.1111/ctr.12559
M3 - Article
C2 - 26094583
AN - SCOPUS:84937162112
VL - 29
SP - 654
EP - 663
JO - Clinical Transplantation
JF - Clinical Transplantation
SN - 0902-0063
IS - 7
ER -